Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Abstract

Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life. (Funded by the National Cancer Institute and AstraZeneca; OlympiA ClinicalTrials.gov number, NCT02032823.).

Keywords

OlaparibSynthetic lethalityBreast cancerHomologous recombinationPoly ADP ribose polymeraseMedicineBRCA2 ProteinPolymeraseGermlineCancer researchAdjuvantPARP inhibitorGermline mutationCancerOncologyMutationInternal medicineDNA repairBiologyGeneticsDNAGene

MeSH Terms

AdultAntineoplastic AgentsBreast NeoplasmsChemotherapyAdjuvantDisease-Free SurvivalDouble-Blind MethodFemaleGenesBRCA1GenesBRCA2Germ-Line MutationHumansMastectomyMiddle AgedPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsReceptorErbB-2

Affiliated Institutions

Related Publications

Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations

Sunil R. Lakhani , J Jacquemier , J P Sloane +38 more

Our study has identified key features of the histologic phenotypes of breast cancers in carriers of mutant BRCA1 and BRCA2 genes. This information may improve the classification...

1998 JNCI Journal of the National Cancer I... 692 citations

Gene-Expression Profiles in Hereditary Breast Cancer

Ingrid Hedenfalk , David Duggan , Y Chen +23 more

Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancers with BRCA2 mutations. Our results suggest that a heritable mutati...

2001 New England Journal of Medicine 1733 citations

A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy

Chris Hunter , Raffaella Smith , Daniel P. Cahill +52 more

Abstract Malignant gliomas have a very poor prognosis. The current standard of care for these cancers consists of extended adjuvant treatment with the alkylating agent temozolom...

2006 Cancer Research 426 citations

Author response: DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis

Ben Taylor , Serena Nik‐Zainal , Yee Ling Wu +6 more

Article Figures and data Abstract eLife digest Introduction Results Discussion Materials and methods References Decision letter Author response Article and author information Me...

2013 4 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 25
Pages: 2394-2405
Citations: 1483
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1483

OpenAlex

Influential

1320

CrossRef

Cite This

APA Style

                            
                                
                                    Andrew Tutt, 
                                
                                    Judy E. Garber, 
                                
                                    Bella Kaufman
                                
                                et al.
                            
                            (2021). 
                            Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. 
                            New England Journal of Medicine
                            , 384
                            (25)
                            , 2394-2405.
                            https://doi.org/10.1056/nejmoa2105215
                        

Identifiers

DOI: 10.1056/nejmoa2105215
PMID: 34081848
PMCID: PMC9126186

Data Quality

Data completeness: 90%